Hims & Hers Health Inc. shares posted their best week on record as a new partnership with Novo Nordisk A/S fuels fresh optimism about the company’s future in weight-loss drugs.

Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Katie Greifeld, Carol Massar and Tim Stenovec. (Source: Bloomberg)

Novo Nordisk A/S plans to sell its weight-loss drugs on Hims & Hers Health Inc.’s platform, according to a person familiar with the matter, ending a highly public feud between the two companies that spiraled into a legal battle last month.

Denmark’s economy is poised to expand at the fastest pace in the Nordic region this year, even as pharmaceutical giant Novo Nordisk A/S grapples with slowing sales, according to the country’s largest lender.

Novo Nordisk A/S will spend €432 million ($507 million) upgrading an Irish factory to produce its hit Wegovy weight-loss pill for markets outside the US, the Irish Times reported Monday.

The weight loss-fueled gains of Danish drugmaker Novo Nordisk A/S are officially a thing of the past.

Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Kristine Aquino, Carol Massar and Tim Stenovec. (Source: Bloomberg)

Novo Nordisk A/S plans to slash the US list prices for its blockbusters Wegovy and Ozempic next year as the drugmaker struggles to claw back a larger share of the obesity market.

An experimental drug Novo Nordisk licensed last year has shown notable weight loss in a mid-stage study in China, boosting the company’s search for newer products that could sustain its growth in the obesity market.

Novo Nordisk’s next-generation obesity shot delivered less weight loss than Eli Lilly rival blockbuster in yet another blow to the Danish company’s attempts to regain lost ground in the weight-loss market. People treated with a standard dose of Novo’s CagriSema in a trial achieved 20.2% weight loss after 84 weeks, compared with 23.6% for Lilly’s tirzepatide. Sam Fazeli of Bloomberg Intelligence joins to discuss. He also breaks down how Merck is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its best-selling cancer drug Keytruda. (Source: Bloomberg)

Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly’s tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks on "Bloomberg Open Interest." (Source: Bloomberg)

Disappointing data from Novo Nordisk A/S is sending shockwaves across equities in Denmark, dragging the wider market down and underscoring how tightly the country’s fortunes are tied to the obesity-drug maker.

Quantum investment firm Quantonation Ventures has raised €220 million ($260 million) for its second fund devoted to physics-based technologies, backed by data center builder ACS SA and Novo Nordisk A/S’s controlling shareholder, among others.

Novo Nordisk says it’s investing in production in central Ireland, doing battle with Eli Lilly

Novo Nordisk says more than 246,000 people are now taking its weight-loss pill. CEO Mike Doustdar sits down with Bloomberg’s Katie Greifeld to discuss GLP-1 supply, pricing and the company’s lawsuit against Hims over alleged obesity drug copycats. (Source: Bloomberg)

Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after the closing bell on Wall Street. Today's guests are TIAA Wealth Management’s Niladri Mukherjee, Quest Diagnostics’s Jim Davis, Baird’s Michael Ha, BD’s Tom Polen, Charles Schwab’s Kevin Gordon, Cox Automotive’s Stephanie Valdez Streaty, Hinge Health’s Daniel Perez, Philips’ Roy Jakobs, Willkie Farr & Gallagher’s Edward Best, and ESPN’s Patrick McEnroe. (Source: Bloomberg)

Bloomberg News Health Reporter Madison Muller reports on the latest on Novo's lawsuit. - Novo Nordisk said it’s suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Hims is breaching the US patent on semaglutide, the active ingredient in Novo’s blockbuster obesity treatments, Novo argued Monday. The US lawsuit attacks not only Hims’ new strategy to launch a copycat pill but also goes after shots that mimic Wegovy and its sister drug Ozempic. The move marks a more aggressive approach for Novo under Chief Executive Officer Mike Doustdar. Until now, the drugmaker’s legal strategy focused on the way that companies like Hims market their products. Novo said this is the first time it has sued over patent infringement for compounded semaglutide. (Source: Bloomberg)

European stocks advanced as Novo Nordisk A/S rallied after a US competitor scrapped a copycat of the Wegovy weight-loss pill.

Novo Nordisk A/S shares rose after Hims & Hers Health Inc. agreed to stop selling a copycat version of the new Wegovy weight-loss pill following US government threats to crack down on knockoffs. Bloomberg's Sam Fazeli reports. (Source: Bloomberg)

Novo Nordisk shares surged at the European market Open, reversing some of last week’s plunge, after Hims & Hers Health pulled a copycat version of the new Wegovy weight-loss pill. The Danish pharma giant's stock rose as much as 8.6% in early Copenhagen trading, clocking its biggest gain so far this year. Hims & Hers said it would stop offering the treatment in a post on X Saturday, a day after the US Food and Drug Administration pledged to crack down on copycat weight-loss drugs.  Elsewhere, sterling fell against the euro to its lowest level since January 22 as the UK political crisis deepened after Starmer’s chief of staff quit on Sunday. The Opening Trade has everything you need to know as markets open across Europe. With analysis you won't find anywhere else, we break down the biggest stories of the day and speak to top guests who have skin in the game. Hosted by Anna Edwards, Guy Johnson and Tom Mackenzie. (Source: Bloomberg)